SCHEMBL23057766

SCHEMBL23057766

Cc1cc(N)ccc1-c1cn(C)c2nc(C(F)(F)F)nc(N)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 2/20 0.36
EIF2AK3 Q9NZJ5 11/20 0.35
HTT P42858 1/20 0.35
GLA P06280 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
PDE4A P27815 2/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
HAVCR2 Q8TDQ0 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C8 P10632 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
EIF2AK2 P19525 1/20 0.31
RIPK1 Q13546 1/20 0.31
EIF2AK1 Q9BQI3 1/20 0.31
EIF2AK4 Q9P2K8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29684355 0.83 CRHR1 (0.39) CRHR1EIF2AK3GAAHAVCR2PRKCI
SCHEMBL23043996 0.83 CRHR1 (0.39) CRHR1EIF2AK3GAAHAVCR2PRKCI
SCHEMBL30062898 0.79 CRHR1 (0.41) CRHR1EIF2AK3HAVCR2CYP3A4EIF2AK2
SCHEMBL23057760 0.79 CRHR1 (0.41) CRHR1EIF2AK3HAVCR2CYP3A4EIF2AK2
SCHEMBL20351734 0.76 SRC (0.49) EIF2AK3CYP3A4EIF2AK2RIPK1EIF2AK1
SCHEMBL23057767 0.73 DYRK1A (0.39) EIF2AK3CYP3A4EIF2AK2RIPK1EIF2AK1
SCHEMBL30060936 0.73 DYRK1A (0.39) EIF2AK3CYP3A4EIF2AK2RIPK1EIF2AK1
SCHEMBL23057770 0.73 EIF2AK3 (0.47) EIF2AK3
SCHEMBL23057545 0.72 PDE4A (0.36) HTTPDE4APDE4BPDE4CPDE4D
SCHEMBL23057764 0.71 HAVCR2 (0.37) EIF2AK3HTTGAATSHRHAVCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. 2022-11-10 US disclosed
WO-2021041975-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. (US) 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS EEF2K, ATF4, MAPKAPK2 CRHR1 2317/4885EIF2AK3 96/4885HTT 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.